Broadfin Capital
VC Fund
New York, United States
Broadfin Capital is a New-York-based company focused on investments in healthcare companies.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 9%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Broadfin Capital invests in
BiotechnologyHealth CareMedicalTherapeuticsPharmaceutical
Stages Broadfin Capital invests in
Post-IPO EquitySeries CFunding Round
Countries Broadfin Capital invests in
United StatesCanadaIreland
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Kevin Kotler
|
|||
Investment Focus
Industry
- Biotechnology 10 (91%)
- Health Care 7 (64%)
- Medical 6 (55%)
- Therapeutics 3 (27%)
- Pharmaceutical 3 (27%)
Stage
- Post-IPO Equity 8 (73%)
- Series C 2 (18%)
- Funding Round 1 (9%)
Country
- United States 9 (82%)
- Canada 1 (9%)
- Ireland 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Kevin Kotler
Managing Member & Portfolio Manager
|
Managing Member & Portfolio Manager | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Edesa Biotech is a clinical-stage private company focused on developing treatments for dermatological and anorectal diseases. The initial focus is on developing novel, safe and potent alternatives to steroids for Allergic Contact Dermatitis, Hemorrhoids, and Anal Fissures. Edesa Biotech’s lead asset, EB01 is a novel non-steroidal anti-inflammatorymolecule for the treatment of allergic contact dermatitis which has already demonstrated statistically significant improvements in multiple clinical studies. | $10.6M / Post-IPO Equity / Feb 13, 2025 | ||
| Heron Therapeutics Inc, formerly A.P. Pharma, Inc. is a specialty pharmaceutical company developing pharmaceutical products using its Biochronomer polymer-based drug delivery platform. The Company’s lead product candidate, APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoingboth moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company’s Biochronomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection. | $76.5M / Post-IPO Equity / Aug 09, 2022 | ||
| At Arch Oncology, they are aiming high to discover and develop new antibody therapeutics to treat patients living with cancer. They are committed to advancing antibodies with best-in-class potential.Their next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative toother agents in this class. | $105M / Series C / Apr 27, 2021 | ||
| Formerly Known as Vasculox. Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses. | $105M / Series C / Apr 27, 2021 | ||
| BioDelivery Sciences is a pharmaceutical company that focuses on pain management and addiction medicine. They are utilizing their novel and proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology to develop and commercialize, either on their own or in partnership with third parties, new applications of proven therapies aimed ataddressing important unmet medical needs. | $50M / Post-IPO Equity / May 17, 2018 | ||
| Strata Skin Sciences is a medical technology company that specializes in dermatology and plastic surgery. Its products include the XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions; and the MelaFind® system used to assist in the identification and management of melanomaskin cancer. | $17M / Post-IPO Equity / Apr 02, 2018 | ||
| Iovance Biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL). The company is preparing for potential regulatory approval and marketing of the first autologous T-cell treatment for solid tumor cancer in the United States. Its goal is to be the leader intumor-infiltrating lymphocyte, or TIL, therapy innovation, development, and delivery for patients with solid tumor malignancies. | $100M / Post-IPO Equity / Jun 03, 2016 | ||
| Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. The Company's molecules, whose systemic exposure is severely restricted, target transporters and receptors, modulating the uptake of nutrients or inducing secretion of key hormones to produce a therapeutic benefit in patients. TheCompany's non-systemic products act from within the intestines to avoid potential side effects that could occur with systemic exposure. The Company's lead product, RDX5791, a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and for prevention of excess dietary sodium absorption, a new treatment modality for high blood pressure. RDX5791 is in phase 2 for IBS-C and a dose-ranging/regimen study for inhibition of excess dietary sodium absorption. Ardelyx is also developing RDX002, a minimally-absorbed, orally administered NaP2b phosphate transport inhibitor for the inhibition of phosphate absorption in patients with chronic kidney disease, and RDX009, a minimally-absorbed, orally administered TGR5 agonist for the treatment of type 2 diabetes through direct induction of intestinal incretins such as GLP-1 and PYY. Both RDX002 and RDX009 are in preclinical development. To date, Ardelyx has raised $56M in venture and angel funding since it was founded in 2007. Ardelyx is located in Fremont, California. | $77.8M / Post-IPO Equity / Jun 22, 2015 | ||
| Aralez Pharmaceuticals operates as a pharmaceutical company. The Company focuses on acquiring, developing, and commercializing products primarily in cardiovascular, pain, and other specialty areas. Aralez Pharmaceuticals serves customers worldwide. | $350M / Post-IPO Equity / Jun 08, 2015 | ||
| Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immuneresponse all human beings have to the bacterium to the cancer itself.ADXS-HPV is being evaluated in four clinical trials for HPV-associated diseases: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI US study), head and neck cancer (CRUK study), and anal cancer (BrUOG). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence. | $23M / Post-IPO Equity / Feb 19, 2015 | ||
| See all 11 investments → | |||
Co-Investors
Adage Capital Management
3 deals together
Avego Healthcare Capital
2 deals together
Cormorant Asset Management
2 deals together
Cowen Healthcare Investments
2 deals together
Eventide
2 deals together
FMB Research
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
47,147 investors
Biotech Investors
23,541 investors
Biotechnology Investors
20,889 investors
Medical Investors
20,530 investors
Health Care VC Funds
35,356 investors
Biotech VC Funds
20,362 investors
Biotechnology VC Funds
18,327 investors
Medical VC Funds
17,653 investors
Health Care Investors in United States
21,541 investors
FAQ
What does Broadfin Capital invest in?
Broadfin Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Post-IPO Equity and Series C stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Broadfin Capital?
Public channels for Broadfin Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Broadfin Capital?
The team at Broadfin Capital includes Kevin Kotler (Managing Member & Portfolio Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
